June 18th 2024
Yimmugo, which was introduced in Europe at the end of 2022, could be on the market in the US within months.
Emergent and Humanigen Form CDMO Compact for COVID-19 Therapeutic Candidate
January 26th 2021Emergent will use its CDMO services to manufacture drug product batches to support the increased supply of the therapeutic candidate in anticipation of a potential emergency use authorization in the first quarter of 2021.
Avid and Argonaut Enter into Manufacturing Solutions Co-Marketing Agreement
July 30th 2020The companies will utilize Avid’s upstream and downstream process development and drug substance manufacturing services in conjunction with Argonaut’s parenteral drug product fill-finish services for the delivery of CGMP parenteral drug products for use in clinical studies.